<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758845</url>
  </required_header>
  <id_info>
    <org_study_id>Pro5Safe</org_study_id>
    <nct_id>NCT04758845</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Safety and Efficacy of New Probiotic Strains in Health Adults</brief_title>
  <official_title>A Randomized, 5 Arm, Parallel, Placebo Controlled Clinical Study to Evaluate Safety and Efficacy of New Probiotic Strains in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deerland Enzymes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deerland Enzymes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to determine the safety of 4 new probiotic strains and to assess their efficacy&#xD;
      in reducing the incidence and/or duration of gastrointestinal problems and infections as well&#xD;
      as respiratory infections in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>45 days</time_frame>
    <description>Participants will be asked to note any adverse events that might occur during 45 days study treatment period in the participant diary 1 and 14 days follow-up period in the participant diary 2 and to call the investigator if any clinically significant events occur. The investigator will review the returned participant diaries together with the participant. Based on the adverse events marked in the diaries and written in medical records the number of adverse event occurrences, their nature and causality will be evaluated in all study regimes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunomodulation</measure>
    <time_frame>45 days</time_frame>
    <description>Evaluate difference in salivary IgA in experimental groups compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regularity</measure>
    <time_frame>45 days</time_frame>
    <description>Evaluate difference in stool consistency according to Bristol stool chart, and regularity of defecation from baseline to day 45 in experimental groups compared to control group and from baseline to end of 14 days follow up period (59 days) in the experimental groups compared to control group. Participants will be asked to track the type of their stool using the bristol stool chart, and times of defecation during the 45 day treatment period and 14 days follow up period in their diaries. On visit 2 and during the follow up phone call the investigator will review the participant diary together with the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI Health</measure>
    <time_frame>45 days</time_frame>
    <description>Assess number of days with gastrointestinal problems in experimental groups compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Health</measure>
    <time_frame>45 days</time_frame>
    <description>Assess number of days with respiratory infections in experimental groups compared to placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Heart Health</measure>
    <time_frame>45 days</time_frame>
    <description>Assess the change in blood lipids from baseline to finish in experimental groups compared to plcaebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation</measure>
    <time_frame>45 days</time_frame>
    <description>Assess the change in cytokines in experimental groups compared to placebo.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Gastrointestinal Health</condition>
  <condition>Respiratory Health</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>Cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume 1 capsule containing 2B CFU containing .5B CFU Bacillus subtilis DE111, .5B CFU Bacillus coagulans CGI314, .5B CFU Bacillus megaterium MIT411, and .5B CFU Bacillus clausii CSI08 for 45 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CGI314</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume 1 capsule containing 1B CFU of Bacillus coagulans CGI314 for 45 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSI08</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume 1 capsule containing 1B CFU of Bacillus clausiiCSI08 for 45 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MIT411</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume 1 capsule containing 1B CFU of Bacillus megaterium MIT411 for 45 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will consume 1 capsule containing maltodextrin for 45 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cocktail</intervention_name>
    <description>Subjects will consume 2B CFU once daily containing .5B CFU DE111, .5B CFU MIT411, .5B CFU CGI314, and .5B CFU CSI08 for 45 days.</description>
    <arm_group_label>Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CGI314</intervention_name>
    <description>Subjects will consume 1B CFU of CGI314 once daily for 45 days.</description>
    <arm_group_label>CGI314</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CSI08</intervention_name>
    <description>Subjects will consume 1B CFU of CSI08 once daily for 45 days.</description>
    <arm_group_label>CSI08</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MIT411</intervention_name>
    <description>Subjects will consume 1B CFU of MIT411 once daily for 45 days.</description>
    <arm_group_label>MIT411</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form. Healthy adults aged 18-65.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a pre-existing adverse events monitored in the study. Presence of a&#xD;
             serious congenital anomaly or chronic medical condition that would contraindicate&#xD;
             participation, including history of major GI surgery, chronic GI illness, abnormal&#xD;
             intestinal anatomy or significant abdominal disorder. Severe chronic illness. Known&#xD;
             immunodeficiency. Use of immunosuppressive agents. Presence of severe immunodeficient&#xD;
             family members. Pregnancy, 6 months postpartum period or currently breastfeeding.&#xD;
             Women of child bearing age planning pregnancy during the course of the study.&#xD;
             Participation in another study. Not able to understand and comply with requirements of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilijana K Besednjak, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Center Nova Gorica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lilijana K Besednjak, MD PhD</last_name>
    <phone>+38653383466</phone>
    <email>lilijana.besednjak.kocijancic@zd-go.si</email>
  </overall_contact>
  <location>
    <facility>
      <name>Health Center Nova Gorica</name>
      <address>
        <city>Å empeter Pri Gorici</city>
        <zip>5290</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilijana K Besednjak, MD PhD</last_name>
      <phone>+38653383466</phone>
      <email>dos.besednjak@zd-go.si</email>
    </contact>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Gastrointestinal Health</keyword>
  <keyword>Respiratory Health</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Antioxidant</keyword>
  <keyword>Chelation of heavy metals</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

